Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.09 USD | +2.37% | -4.05% | -33.24% |
Business Summary
Number of employees: 158
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapies
100.0
%
| 10 | 100.0 % | 2 | 100.0 % | -83.69% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 10 | 100.0 % | 2 | 100.0 % | -83.69% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bernard Coulie
CEO | Chief Executive Officer | 58 | 01/16/01 |
- | - | ||
Keith Cummings
DFI | Director of Finance/CFO | 47 | 01/18/01 |
Chief Tech/Sci/R&D Officer | - | 04/21/04 | |
Eric Lefebvre
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/18/01 |
Scott Turner
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/21/01 |
Investor Relations Contact | - | 01/20/01 | |
Minnie Kuo
PRN | Corporate Officer/Principal | - | 14/23/14 |
Corporate Officer/Principal | - | - | |
Rik Derynck
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 12/21/12 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 01/16/01 |
Gayle Crowell
BRD | Director/Board Member | 73 | 08/20/08 |
Ho Young Huh
CHM | Chairman | 54 | 01/17/01 |
Bernard Coulie
CEO | Chief Executive Officer | 58 | 01/16/01 |
Thomas McCourt
BRD | Director/Board Member | 66 | 06/23/06 |
Darren Cline
BRD | Director/Board Member | 59 | 06/23/06 |
John Curnutte
BRD | Director/Board Member | 72 | 01/17/01 |
Smital Shah
BRD | Director/Board Member | 48 | 14/19/14 |
Katharine Knobil
BRD | Director/Board Member | 60 | 14/22/14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 60,239,176 | 56,275,539 ( 93.42 %) | 0 | 93.42 % |
Company contact information
Pliant Therapeutics, Inc.
260 Littlefield Avenue
94080, South San Francisco
+650 481 6770
http://www.pliantrx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.24% | 729M | |
+26.47% | 664B | |
+26.74% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.43% | 234B | |
+4.71% | 199B | |
-9.53% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- PLRX Stock
- Company Pliant Therapeutics, Inc.